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Abstract
We devised a novel procedure to identify human cancer genes acting in a recessive manner. Our strategy was to combine
the contributions of the different types of genetic alterations to loss of function: amino-acid substitutions, frame-shifts, gene
deletions. We studied over 20,000 genes in 3 Gigabases of coding sequences and 700 array comparative genomic
hybridizations. Recessive genes were scored according to nucleotide mismatches under positive selective pressure, frame-
shifts and genomic deletions in cancer. Four different tests were combined together yielding a cancer recessive p-value for
each studied gene. One hundred and fifty four candidate recessive cancer genes (p-value,1.5610
27, FDR=0.39) were
identified. Strikingly, the prototypical cancer recessive genes TP53, PTEN and CDKN2A all ranked in the top 0.5% genes. The
functions significantly affected by cancer mutations are exactly overlapping those of known cancer genes, with the critical
exception for the absence of tyrosine kinases, as expected for a recessive gene-set.
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Introduction
A variety of approaches have been applied to the identification of
cancer genes [1]. Procedures have been developed that allowed
identificationof genescausative of cellulartransformation[2,3], and
of complex processes such as invasiveness and metastasis [4]. In
vitro and in vivo methods, using cellular or animal models, led
generally to the discovery of dominant cancer genes, or oncogenes.
On the other hand, tumor suppressors have been discovered mainly
by molecular genetics approaches. Such is the need of identifying
additional tumor suppressors, or recessive cancer genes, that new
tests for loss-of-function continue to be developed [5].
Many well-characterized cancer genes harbor somatic base
substitutions or small insertion/deletions. For example, coding
region frame-shifts and point mutations account for 75% of the
somatic mutations in CDKN2A and TP53, two major tumor
suppressor genes [6,7,8]. The oncogene B-raf, first described over
20 years ago, was also shown to be mutated in some human
cancers [9], alongside PI3K and some tyrosine phosphatases [10].
Meanwhile, other cancer genes have been discovered through the
phenomenon of inherited predisposition. Familial cancer is rare in
comparison to non-hereditary cancer, but a number of recessive
genes have been identified using linkage analysis [11,12]. Large
scale super-family sequencing projects, i.e. the kinome and
phosphatome projects, followed and showed that, although
missense mutations are found in some members of these two
superfamilies, they are not a common ground for somatic cancer
mutations. Greenman and co-workers [13] undertook compre-
hensive sequencing of 518 protein-kinase-encoding genes in 210
cancers. Kinases have been implicated in many aspects of
tumorigenesis and several have now been validated as targets for
drug therapy [14]. In their analysis of the collection of cellular
kinases, the kinome, Greenman et al. [13] identified 1,000
mutations. Mutations were relatively common in cancers of the
lung, stomach, ovary, colon and kidney, and rare in cancers of the
testis and breast, and in carcinoid tumors, which are usually found
in the gastrointestinal tract. Tumors with defects in DNA-
mismatch repair harbored large numbers of mutations, whereas
other types of tumor revealed no detectable mutations. To
distinguish driver from passenger mutations, Greenman et al.
used a statistical model comparing the observed-to-expected ratio
of synonymous (no amino-acid change) mutations with that of
non-synonymous (altered amino acid) mutations. An increased
proportion of non-synonymous mutations implies selection
pressure during tumorigenesis. Overall, they identified 158
predicted driver mutations in 120 kinase genes. In contrast to
the recurrent mutations in BRAF in malignant melanomas [15]
most kinase mutations identified across different tumor types were
therefore single hits. More recently, Wood and co-workers [16]
used a different strategy, but reached similar conclusions, with the
complete sequencing of 20,857 transcripts from 18,191 genes in a
limited number of tumors (11 breast and 11 colon). The high
number of automatically detected DNA mutations provided
immediately the following question: how to identify from a
potentially high number of sequence mismatches those that are
causative of cancer pathogenesis. A series of subsequent filters
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change) and a similar amount were single nucleotide polymor-
phisms (SNPs). The final number of mutations which were defined
as truly somatic affected more than 1000 genes. Interestingly, few
common driver mutations were identified among the kinase genes
in these studies. This is consistent, for example, with the finding
that only 1 out of 18 members of the PI3K family had somatic
mutations in cancer [17].
Interesting observations can be made from an accurate global
study of the mutations reported in cancer. Futreal et al. [18]
conducted such an extended census from bibliography indicating
that as many as 299 genes contribute to human cancer. However
70% of these genes are associated with leukemias, lymphomas and
mesenchymal tumors, which account for only 10% of cancer
incidence. Furthermore about 75% of those genes are associated
with translocations, and at least 90% of listed cancer genes are
dominant at the cellular level (i.e. activated oncogenes, fusion
oncoproteins). Nevertheless, it is generally recognized that the vast
majority of germline mutations resulting in cancer predisposition
are recessive [18]. Thus it seems likely that most of the cancer
genes are recessive and remain still undiscovered.
For these reasons we devised a novel method for the
identification of candidate recessive cancer genes from genome-
scale datasets. We applied our novel procedure to mine data from
sequences and comparative genomic hybridizations. Our method
takes account of the different gene inactivation modes, ranging
from point mutations to whole gene deletions. The assumption
underlying our investigation was that, by studying cancer genes
from different mutational perspectives and combining the
respective probabilities, sequencing noise and polymorphisms
could be filtered out and bona fide recessive cancer genes would be
identified.
Results
Harvesting candidate mutations from ESTs
In this paper, a novel method was applied to the identification of
genes mutated in non-hereditary human cancers (Figure 1). The
procedure gathered sequence information from the expression
sequence tag (EST) database and an appropriate algorithm was
tailored to extract information from ‘‘low quality’’ sequence data.
The procedure analyzed more than 3610
9 nucleotides of human
coding sequence in over 5,600,000 ESTs derived from both
healthy and cancerous tissues and cell lines. ESTs are potentially
very valuable for mutation studies since they represent cloned
single alleles, but are also unverified sequences, with a high rate of
sequencing errors [19,20]. Therefore, in order to exploit the full
potential of ESTs we had to develop a method for the detection of
bona fide ‘‘cancer’’ mutations in a context of frequent sequencing
errors or, at best, polymorphisms. Although previous work [19]
attempted to evaluate sequencing error rate in ESTs, we followed
an alternate route. Our procedure was based on the assumption
that the rate of sequencing errors was constant for each human
gene, at each nucleotide position. As a corollary, we assumed that
the ‘‘gene/position-specific sequencing error rate’’ was constant
across normal and cancer EST libraries. Since base composition,
context and sequence are by definition constant within each
different human gene, we believed these assumptions were safe.
Only exceptions would be due to the tumors harboring DNA
repair defects.
High sequencing noise was expected to be present in the
heterogeneous EST database and cancer is a complex multi-
faceted genetic disease, therefore a single statistical test would not
result in reliable selection of cancer genes. Furthermore, we
wanted to focus on recessive genes, inactivated by the occurring
events. Thus, to assay the different mutational modes of recessive
cancer gene, we accordingly devised a number of mutational tests.
The statistical tests were eventually combined to identify the genes
that are often inactivated in cancer.
Starting from the RefSeq human mRNA repository, 27,184
sequences (defined Queries) were aligned to more than 5.6 million
human EST sequences, from 7574 different EST libraries, for a
total of almost 3.0 Gbases of coding sequence. BLASTs [21] were
run for each query versus the ESTs and 3,839,543 successful
alignments were produced (stored in the Alignments SQL table of
the Cancer Mutome database) for 24,932 human queries (Stats
database table). An average of 150 hits (high scoring pairs, HSP. or
sequences) was produced for each query (human gene or splicing
variant). The quality control of the BLAST alignments was of the
foremost importance for our strategy. In order to minimize the
mining of technical errors we defined a stringent threshold for
alignment quality (expect#1E-21) and the low quality ends of
alignments were discarded. All (43,965,904) nucleotide mismatch-
es, and gaps/insertions, were recorded in the database Mutations
table. Amino acid (AA) substitutions and premature stops
(33,614,754 mismatches) were then selected from the alignments
(AA_Mutation table). To reduce the complexity, and the expected
number of false positives, we decided to evaluate only those genes
with a high number of mismatches (irrespective of the samples
cancer status). A pre-processing based on inter-quartile range
(IQR) was therefore applied and 8,972 genes (IQR higher than
0.5) were retained for further cancer mutation assays. These genes
were sufficiently rich in putative mutations (mismatches) to fulfill
the role of potential cancer gene candidates.
The first component of our strategy was the identification of
genes harboring inactivating point mutations. We evaluated the
Figure 1. The rationale for selection of candidate recessive
cancer genes. The diagram shows the steps in the procedure for the
evaluation of mutation probabilities and the data flow towards the
identification of candidate recessive cancer genes. Molecular data were
extracted from public databases (dbEST and GEO at NCBI, and Stanford
Microarray Database). A very large number of alignments (over 4.5
million) was obtained for over 24,000 human genes from BLAST analysis
of 3 Gbases of EST sequences. The alignments were parsed to extract
mismatches which were deposited in the Cancer Mutome local SQL
database. The mismatches were then evaluated by specific procedures
to associate mutational p-values to each human gene. In parallel,
almost 20,000 human genes were assayed from 744 array CGH to define
their propensity to deletion in cancer. The specific mutational p-values
were combined to produce a recessive cancer p-value. A genome
subset of 154 genes, among which TP53, PTEN, CDKN2A and CDKN2B
were present, was selected (cancer p-value,1.5610
27).
doi:10.1371/journal.pone.0003380.g001
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the amino acid sequence, and consequences on the reading frame.
Our procedure was thus tailored to consider statistically all the
above features of a point mutation.
Data mining for amino-acid substitutions and premature
terminations
We defined pAA as the probability that a gene displays an
excess of amino acids substitutions in cancer when compared to
non cancer samples. pNSSR, instead, indicates the probability that
the significant amino acids substitutions in the cancer samples are
under positive selection pressure. To detect short range clustering
of cancer mutations, common in cancer recessive genes, and to
balance out noise, i.e. sequencing errors, we chose a paired t test
coupled to a sliding window. We normalized the counts of the
mismatches in the two classes, cancer and control, by using a gene
specific and position specific factor. Null mismatch counts were
adjusted to unity, prior to normalization. The normalization
values were obtained, for each gene and at each nucleotide
position, as the local ratios of the sequenced nucleotides in the
cancer and control samples. The paired t test (cancer vs. control,
paired for codons) was applied to a sliding window with a length of
25 codons. To perform a robust assay a codon was evaluated only
when aligned at least 10 times in each class (cancer and control).
Gene specific confidence limits for T scores where generated by
bootstrap analysis and a threshold p-value of 0.05 was used to
select the significant amino acid positions. For each human gene, a
p-value (pAA) was finally associated to the sum of the peaks
corresponding to the significant T scores. A sequence mismatch
was recorded only once for each EST library.
An over-estimation of pAA could be due to passenger
mutations, such as those produced by altered DNA repair systems,
prevalent in some cancer. Since passenger mutations should be
randomly distributed over the genome, an additional test was
therefore implemented to refine the pAA. The ratio of non-
synonymous (NS) to synonymous (S) DNA mutations is a measure
of the selective pressure during tumor progression, as synonymous
alterations are unlikely to exert a growth advantage and will be
selectively lost [17]. Furthermore, mismatches due to sequencing
errors, as well as differential representation (cancer to normal
differential expression), are all expected to be neutral with respect
to the NS to S ratio. The codons significant for amino acid
substitutions (p,0.05) were therefore assayed for positive pressure.
As a proof-of-concept, the NS/S ratios in the TP53 mutated
region were analyzed by paired t test (p,0.033, FDR=0.092) and
revealed higher values in cancer than in control. Thus we applied
the NS to S ratio test to each gene, in cascade after that for the
local mutation frequency (pAA) described above. Bootstrap was
again used to define the p-values. The probability of a cancer
protein having frequent amino acid changes (pAA) coupled to
selective positive pressure in cancer (pNSSR), two events which are
not independent, was defined as the average of the two respective
p-values (pAA-NSSR).
Data mining for frame-shifts in cancer ESTs
Having defined for each human gene a p-value for causal amino
acid substitutions in sporadic cancers, we needed a corresponding
index for gene inactivation due to open reading frame shifts in
exons. Cancer genes can be disrupted by micro-insertions or -
deletions in their coding sequence, resulting in an altered primary
structure. A genome wide survey of our mismatch database
indicated that single nucleotide alterations were by far the most
common insertions/deletions in ESTs. We indicated with pFrame-
shift the probability that a gene had an excess of frame-shifts, due
to single nucleotide deletions/insertions in cancer, compared to
control tissues. We tested the hypothesis that these mutations were
frequent in cancer genes, by studying again TP53. Our assay
showed that single nucleotide frame-shifts associated to cancer
were non-randomly enriched in TP53. When looking for frame-
shifts induced by 1 nucleotide insertions/deletions, an analogous
test to that for pAA was designed, as detailed in Experimental
Procedures, to generate pFrameshift.
Identification of deleted genes in cancer by high
resolution array comparative genomic hybridization
Cancer genes can be affected in their genomic structure by large
amplifications and deletions. Recessive cancer genes are expected
to be deleted or otherwise inactivated and this component must be
included in our mutational model. We therefore assigned to each
human gene p-values for deletion in cancer. To obtain such p-
values, we compiled data from high resolution comparative
genomic hybridizations of 744 tumors into the GeoSoft database.
We used array CGH (aCGH), obtained from GEO (NCBI) and
SMD (Stanford Microarray Database), with sufficiently high
resolution to distinguish the human genes (information for samples
and datasets in supplemental Table S1). Each tumor sample was
compared to a healthy control sample on a two channel
oligonucleotide-based platform. The human genes were evaluated
in each sample by using the normalized log2 ratio (tumor over
control). Different probes related to the same gene were averaged.
Gene symbols were used as keys to unequivocally identify a gene
within and across platforms. Data were normalized according to
the providers. As a pre-processing step we reduced the assay
complexity by retaining only those genes with high variability
(standard deviation of log2 ratio.0.2). Then, for each gene we
computed the percentiles of the log2 ratios (only for genes
measured in at least 300 samples). A gene affected by deletions in
tumors would possess a low (negative) log2 ratio 5
thpercentile,
while one with amplifications would display a high (positive) 95
th
percentile.
Bootstrap analysis (random swap between the tumor and
control channels) was used to simulate gene specific 5
th and 95
th
percentiles. Then, gene specific p-values for deletions (pDeletion)
were finally calculated as the percentage of simulated 5
th
percentiles exceeding the real 5
th percentiles. At this stage, we
had to take in consideration two phenomena, associated to aCGH
but not linked to cancer: sex chromosomes and polymorphic
structural copy number variations (CNVs). The control sample in
aCGHs was frequently from male (more than 50% of aCGHs),
while roughly half of the tumors were of female origin and thus
lacked the Y-chromosome. Therefore the Y-chromosome genes
were expected to appear as deleted, or better ‘‘pseudo-deleted’’.
Conversely, we expected the X chromosome genes, except for
those belonging to the pseudo-autosomal region, to appear as
‘‘pseudo-amplified’’. Genes located in the sex chromosomes
indeed behaved correctly, as shown in detail for the pseudo-
autosomal region 1 (PAR1) in Xp22 (supplemental Figure S1).
Polymorphic CNVs, from normal population variability and not
linked to cancer, should also lead to large fold-changes, resulting in
high 95
th or low 5
th percentiles. However, we expected that
polymorphic CNVs, not associated to cancer, would not display
significant pDeletion values. In fact their 5
th percentiles would not
qualify as significant after the random swap simulation. CDKN2A
and CDKN2B were identified as the most deleted genes in human
cancers; PTEN, ATM, and TP53 were also identified as deleted (p-
values,0.001). Three thousand and three hundred seventy four
genes were significantly deleted (p,0.001).
Mutated Genes in Cancer
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recessive cancer genes
Cancer genes are affected by different types of point mutations
and of chromosomal alterations. We defined a candidate cancer
gene as recessive when affected by mutations potentially leading to
loss of function; i.e. when it was frequently mutated in its coding
region and frequently altered in its genomic structure, in particular
deleted. The combination of the different genome wide tests
produced a p-value for recessive cancer genes. The recessive
cancer gene (pRecessiveCancer) p-value was defined as the
product of the three p-values (pAA-NSSR, pFrameshift, pDele-
tion). One hundred and fifty four human genes were included in
the final candidate gene list after combinatorial mutation analysis
was performed (pRecessiveCancer,1.5610
27). The number of
cancer recessive genes in a simulation by random association of the
four mutation tests was of 60.5 (false detection rate of 0.39). The
selection by the combinatorial approach appeared to be specific,
since three classical recessive cancer genes, TP53 (16
th position),
PTEN (92
nd) and CDKN2A (135
th) were detected. When we
compared the candidate gene-set to the whole genome, no major
bias emerged towards gene size and structural polymorphisms, as
expected from a well-behaved statistical procedure. The recessive
cancer gene sizes did not differ significantly from that of the whole
human genome (supplemental Figure S2). When we considered
copy number variations, the cancer gene-set contained 15
polymorphic CNVs (15/154 or 10%) while 13.6% of all genes
scored for pDeletion contained at least one CNV. This difference
in proportion was not significant (p..0.05), suggesting that there
was no false enrichment for CNVs by our method, as expected by
the design of the algorithm.
Gene ontology and functional analysis
The mechanisms and functional pathways associated with the
cancer recessive genes were statistically evaluated. The enrichment
in Gene Ontology (GO) terms was assessed by using EASE, at
http://david.abcc.ncifcrf.gov. The biological processes significant-
ly affected in the cancer gene set are listed in supplemental Table
S2. The significant GO terms grouped by EASE functional
clustering were: ATP/nucleotide binding, cell death/apoptosis,
cell cycle, mitochondrion, RNA binding, methylation, tumor
suppressor, DNA metabolism and DNA repair (EASE enrichment
score .2, EASE P-value,1610
24, Benjamini p-value,0.01). A
highly overlapping functional spectrum was obtained for the
Cancer Census genes [18]. The most notable exceptions to the
overlapping ontologies in the two cancer gene-sets were related to
‘‘protein tyrosine kinases’’, absent from the candidate recessive list.
These proteins are one of the most represented classes of
oncogenes, or dominant cancer genes. A functional classification
similar to that of EASE was obtained with BinGO and Cytoscape
(data not shown), where some of the most significant cellular
processes identified were involved in cancer pathogenesis, such as
cell cycle, cell death/apoptosis (corrected p-value,1610
23).
Finally, we generated a control set of human genes by random
associating the p-values from the four mutation tests. When EASE
and BinGO were applied to this control set no significant GO
terms were identified.
Discussion
We devised and applied a multi-tier genome-wide data mining
assay towards the identification of genes prone to ‘‘recessive-type’’
mutations in cancer. The p-values resulting from each tier were
combined to produce a ‘‘recessive cancer gene’’ p-value (Table 1
and 2). Three of the most notable cancer recessive genes, i.e.
TP53, PTEN and CDKN2A, ranked 16
th,9 2
nd and 135
th,
respectively, among all tested human genes. The block diagram
of our rationale and the data flow are shown in Figure 1. The tests
can be subdivided into two groups: one for detection of point
mutations (amino acid substitutions and frame-shifts) and one for
structural alterations (large deletions). In principle we could have
also used a test for partial gene deletions, but in ESTs intra-gene
rearrangements can be confounded with alternative exon splicing.
The probability of a protein having amino acid mutations and
frame-shifts in cancer, events which are independent, was defined
as the product of the respective p-values. Just using these two tests,
the prototypical TP53 and PTEN cancer genes ranked 205
th and
233
rd out of 27,184 evaluated human transcripts (p-val-
ue,1610
24). Additionally, two other well-known recessive cancer
genes, CDKN2A and CDKN2B, also had significant p-values, albeit
lower rankings (p,0.0025 and FDR=0.019, respectively). This
behavior was expected for genes with small coding regions, which
might be more commonly deleted than mutated [6]. Their
presence in the significant point mutations cancer gene-set, even at
this intermediate stage, reassured us of the selection capabilities of
our algorithm. Nevertheless this early classification, based entirely
on point mutations, was compiled only from two mutation tests;
thus, relying on EST sequencing data, it was still not reliable
according to our model which incorporated an additional
mutation mode. It should be noted that we did not set to identify
translocations, alterations expected to be dominant at the cellular
level and therefore not suited to our quest for recessive genes.
The last test, based on aCGH analysis, confirmed that a very
large portion of the human genome is frequently deleted in cancer.
As expected for our 2-channels aCGH procedure, we correctly
detected sex chromosome genes as differentially represented in the
genome screens. In particular, owing to the resolution of our
structural assay, the genes from the pseudo-autosomal region 1
were identified as normal diploid (supplemental Figure S1). Most
importantly, we would expect that polymorphic CNVs had not
filtered through the aCGH assay. Indeed, only a small percentage
of cancer genes coincided with polymorphic CNVs and this
percentage is even smaller than expected by chance (Table 2).
The number of deletions detected by aCGH in the cancer
genome is very high (more than 10% of human genes were deleted
in cancer). Notwithstanding this deletion excess, when all mutation
modes are included, the number of candidate genes is less than
0.5% of the analyzed human genome.
The cancer gene products are involved in biological processes
such as cell cycle, DNA repair and apoptosis, in agreement with
literature. The same functional terms are also associated to the
genes in the COSMIC Cancer Census [18]. Strikingly, tyrosine
kinases, dominant oncogenes, present in the Cancer Census, were
absent from our cancer gene-set, in agreement with the selection
for recessive genes.
Some strong limitations are inherent to our approach. It is
unlikely that the recorded frame-shifts are polymorphisms, since
they alter the primary structure of the gene products. Conversely,
they might be very often results of sequencing errors. For this
reason, we chose to filter out as much as possible the sequencing
errors by using a paired t test over a sliding window. Another
controversy might be related to the somatic character of the
detected mutations. Since there are virtually no germ-line
sequences corresponding to the tumor libraries in the EST
database, there can not be any formal demonstration that the
selected genes correspond to somatic mutation targets. We can not
establish how many of the detected mismatches are real mutations,
nor how many of them are truly of somatic origin. We could only
attach to each human gene a p-value for the excess of mismatches
Mutated Genes in Cancer
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GENE SYMBOL pDeletion pAA pNSSR pAA-NSSR pFrameshift pRecessive Cancer
NASP 5.00E-05 0.0005 0.0005 0.0005 0.0005 1.25E-11
CCNB1 0.0001 0.0005 0.0005 0.0005 0.0005 2.50E-11
DDX21 0.0002 0.0005 0.0005 0.0005 0.001 1.00E-10
DHX9 5.00E-05 0.0005 0.0005 0.0005 0.004 1.00E-10
GANAB 5.00E-05 0.0005 0.0005 0.0005 0.004 1.00E-10
ILF3 0.0005 0.0005 0.0005 0.0005 0.0005 1.25E-10
AIPL1 5.00E-05 0.002 0.011 0.0065 0.0005 1.63E-10
NOLC1 5.00E-05 0.004 0.003 0.0035 0.001 1.75E-10
MYO1C 5.00E-05 0.004 0.014 0.009 0.0005 2.25E-10
NUDC 0.0012 0.0005 0.0005 0.0005 0.0005 3.00E-10
PGAM1 0.002 0.0005 0.0005 0.0005 0.0005 5.00E-10
IPO4 0.0003 0.003 0.0005 0.0018 0.001 5.25E-10
XRCC5 5.00E-05 0.0005 0.0005 0.0005 0.021 5.25E-10
MTO1 5.00E-05 0.0005 0.0443 0.0224 0.0005 5.60E-10
ANP32B 5.00E-05 0.006 0.0421 0.0241 0.0005 6.02E-10
TP53 5.00E-05 0.022 0.031 0.0265 0.0005 6.63E-10
AFG3L2 5.00E-05 0.013 0.002 0.0075 0.002 7.50E-10
FAF1 5.00E-05 0.0737 0.006 0.0398 0.0005 9.96E-10
CALR 0.002 0.0005 0.0005 0.0005 0.001 1.00E-09
SREBF2 0.004 0.0005 0.0005 0.0005 0.0005 1.00E-09
XRCC6 5.00E-05 0.007 0.002 0.0045 0.005 1.12E-09
ARMC8 5.00E-05 0.002 0.0005 0.0013 0.02 1.25E-09
GTPBP4 5.00E-05 0.005 0.002 0.0035 0.008 1.40E-09
HSPA4 0.0004 0.016 0.001 0.0085 0.0005 1.70E-09
HDAC1 5.00E-05 0.001 0.0005 0.0008 0.0486 1.82E-09
PGD 5.00E-05 0.075 0.0005 0.0378 0.001 1.89E-09
VCP 0.002 0.0005 0.0005 0.0005 0.002 2.00E-09
ATXN2L 0.0025 0.0005 0.0005 0.0005 0.002 2.50E-09
RPL6 0.001 0.001 0.009 0.005 0.0005 2.50E-09
SARS 5.00E-05 0.0952 0.007 0.0511 0.001 2.56E-09
NCL 0.0001 0.005 0.001 0.003 0.01 3.00E-09
PTPRC 0.012 0.0005 0.0005 0.0005 0.0005 3.00E-09
SMARCA4 0.012 0.0005 0.0005 0.0005 0.0005 3.00E-09
CCT3 0.0004 0.012 0.004 0.008 0.001 3.20E-09
NET1 5.00E-05 0.01 0.001 0.0055 0.013 3.58E-09
HNRPD 5.00E-05 0.011 0.0005 0.0057 0.013 3.74E-09
SQSTM1 0.01 0.001 0.0005 0.0008 0.0005 3.75E-09
TUBB2C 0.002 0.0005 0.007 0.0037 0.0005 3.75E-09
C1QBP 0.002 0.001 0.007 0.004 0.0005 4.00E-09
TRAP1 0.002 0.0005 0.0005 0.0005 0.004 4.00E-09
ALDOA 0.018 0.0005 0.0005 0.0005 0.0005 4.50E-09
RNASEH2A 5.00E-05 0.1183 0.0651 0.0917 0.001 4.59E-09
DDX24 0.002 0.002 0.0005 0.0013 0.002 5.00E-09
ILVBL 5.00E-05 0.019 0.001 0.01 0.01 5.00E-09
SERPINB3 5.00E-05 0.1205 0.2837 0.2021 0.0005 5.05E-09
UQCRC1 5.00E-05 0.016 0.0005 0.0083 0.016 6.60E-09
EEF2 0.028 0.0005 0.0005 0.0005 0.0005 7.00E-09
NUSAP1 5.00E-05 0.001 0.008 0.0045 0.033 7.43E-09
DNAJC11 0.0002 0.1653 0.008 0.0866 0.0005 8.66E-09
HSP90AA1 0.036 0.0005 0.0005 0.0005 0.0005 9.00E-09
Mutated Genes in Cancer
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MYH9 5.00E-05 0.0709 0.002 0.0365 0.005 9.12E-09
HK1 5.00E-05 0.01 0.001 0.0055 0.034 9.35E-09
IARS 0.01 0.003 0.001 0.002 0.0005 1.00E-08
YBX1 0.004 0.0005 0.0005 0.0005 0.005 1.00E-08
HDLBP 0.03 0.0005 0.001 0.0008 0.0005 1.12E-08
EWSR1 0.02 0.0005 0.002 0.0013 0.0005 1.25E-08
DHX15 5.00E-05 0.0456 0.0005 0.023 0.011 1.27E-08
SERPINB4 5.00E-05 0.3571 0.6667 0.5119 0.0005 1.28E-08
POLR2A 5.00E-05 0.038 0.005 0.0215 0.012 1.29E-08
ALG14 5.00E-05 0.098 0.1023 0.1002 0.003 1.50E-08
PRMT1 0.002 0.003 0.012 0.0075 0.001 1.50E-08
COX4NB 5.00E-05 0.001 0.005 0.003 0.1047 1.57E-08
SPTBN1 5.00E-05 0.026 0.004 0.015 0.021 1.58E-08
PTPRF 5.00E-05 0.0455 0.0005 0.023 0.014 1.61E-08
KHDRBS1 5.00E-05 0.117 0.013 0.065 0.005 1.62E-08
PABPC1 0.002 0.0005 0.003 0.0018 0.005 1.75E-08
CTNNA1 0.018 0.0005 0.0005 0.0005 0.002 1.80E-08
DDB1 0.018 0.0005 0.0005 0.0005 0.002 1.80E-08
GNB2L1 0.074 0.0005 0.0005 0.0005 0.0005 1.85E-08
WDR1 0.002 0.003 0.001 0.002 0.005 2.00E-08
AARS 0.024 0.003 0.0005 0.0018 0.0005 2.10E-08
NDE1 0.0001 0.012 0.002 0.007 0.03 2.10E-08
NQO1 0.002 0.002 0.0005 0.0013 0.009 2.25E-08
RUVBL2 5.00E-05 0.006 0.1778 0.0919 0.005 2.30E-08
ZWINT 5.00E-05 0.0496 0.003 0.0263 0.018 2.37E-08
HP1BP3 0.0007 0.002 0.006 0.004 0.009 2.52E-08
WDR79 5.00E-05 0.0501 0.002 0.026 0.02 2.60E-08
SLC25A6 0.002 0.0005 0.005 0.0027 0.005 2.75E-08
TYMS 5.00E-05 0.037 0.009 0.023 0.024 2.76E-08
SLC25A3 0.06 0.0005 0.0005 0.0005 0.001 3.00E-08
ACLY 5.00E-05 0.0798 0.02 0.0499 0.014 3.49E-08
ALDH3A1 0.14 0.0005 0.0005 0.0005 0.0005 3.50E-08
TTC8 5.00E-05 0.015 0.1626 0.0888 0.008 3.55E-08
YME1L1 5.00E-05 0.0403 0.015 0.0276 0.026 3.59E-08
ATP5A1 5.00E-05 0.029 0.008 0.0185 0.039 3.61E-08
MRPS2 5.00E-05 0.007 0.0915 0.0493 0.015 3.69E-08
HNRPH3 5.00E-05 0.0816 0.0005 0.0411 0.018 3.70E-08
IMMT 0.004 0.038 0.004 0.021 0.0005 4.20E-08
IMPDH2 0.006 0.014 0.0005 0.0073 0.001 4.35E-08
NCKAP1 5.00E-05 0.0417 0.0745 0.0581 0.015 4.36E-08
TTLL12 5.00E-05 0.019 0.01 0.0145 0.0606 4.39E-08
PTEN 0.002 0.0721 0.017 0.0445 0.0005 4.45E-08
WBSCR16 0.182 0.0005 0.0005 0.0005 0.0005 4.55E-08
XPNPEP1 5.00E-05 0.0926 0.0005 0.0465 0.02 4.65E-08
SREBF1 5.00E-05 0.0651 0.3175 0.1913 0.005 4.78E-08
CCDC5 5.00E-05 0.0907 0.005 0.0479 0.021 5.02E-08
DDX19B 5.00E-05 0.007 0.0005 0.0037 0.2685 5.03E-08
MAPK6 5.00E-05 0.0692 0.2286 0.1489 0.007 5.21E-08
MAP4 5.00E-05 0.0442 0.0005 0.0223 0.0469 5.24E-08
PHB2 0.22 0.0005 0.0005 0.0005 0.0005 5.50E-08
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SAE1 0.016 0.0005 0.0005 0.0005 0.007 5.60E-08
TALDO1 5.00E-05 0.1008 0.063 0.0819 0.014 5.73E-08
AHCY 0.23 0.0005 0.0005 0.0005 0.0005 5.75E-08
GTF3C1 0.0001 0.0496 0.001 0.0253 0.023 5.82E-08
PRPF19 0.002 0.0549 0.005 0.0299 0.001 5.99E-08
LASP1 5.00E-05 0.0522 0.007 0.0296 0.0409 6.06E-08
TRIP10 5.00E-05 0.1418 0.01 0.0759 0.016 6.07E-08
HSPD1 0.244 0.0005 0.0005 0.0005 0.0005 6.10E-08
EIF4G2 0.016 0.0005 0.015 0.0077 0.0005 6.20E-08
SFN 0.17 0.0005 0.001 0.0008 0.0005 6.38E-08
TPM3 0.274 0.0005 0.0005 0.0005 0.0005 6.85E-08
ZNF259 5.00E-05 0.004 0.011 0.0075 0.1896 7.11E-08
MAD2L2 5.00E-05 0.0529 0.0713 0.0621 0.024 7.45E-08
GSK3B 5.00E-05 0.0969 0.2139 0.1554 0.01 7.77E-08
SH3BP5 0.003 0.0531 0.002 0.0276 0.001 8.27E-08
CNDP2 5.00E-05 0.0798 0.004 0.0419 0.0407 8.53E-08
PRKD2 5.00E-05 0.1108 0.1208 0.1158 0.015 8.69E-08
CAPG 0.142 0.0005 0.002 0.0013 0.0005 8.87E-08
CAPNS1 0.042 0.0005 0.008 0.0043 0.0005 8.93E-08
YY1 5.00E-05 0.2286 0.0988 0.1637 0.011 9.00E-08
ACSL5 5.00E-05 0.1375 0.0581 0.0978 0.019 9.29E-08
CCT6A 0.382 0.0005 0.0005 0.0005 0.0005 9.55E-08
RPUSD3 5.00E-05 0.1418 0.015 0.0784 0.025 9.80E-08
SBF1 0.006 0.008 0.0005 0.0043 0.004 1.02E-07
YWHAE 5.00E-05 0.031 0.024 0.0275 0.0739 1.02E-07
XPO1 0.274 0.0005 0.001 0.0008 0.0005 1.03E-07
CRELD2 5.00E-05 0.022 0.029 0.0255 0.0818 1.04E-07
PDCD10 5.00E-05 0.03 0.015 0.0225 0.0926 1.04E-07
HNRPF 5.00E-05 0.023 0.024 0.0235 0.0903 1.06E-07
RFT1 5.00E-05 0.03 0.005 0.0175 0.1231 1.08E-07
BAX 5.00E-05 0.3922 0.2326 0.3124 0.007 1.09E-07
EFTUD2 0.446 0.0005 0.0005 0.0005 0.0005 1.11E-07
EEF1D 0.448 0.0005 0.0005 0.0005 0.0005 1.12E-07
FDPS 0.032 0.001 0.013 0.007 0.0005 1.12E-07
CDKN2A 5.00E-05 0.012 0.0579 0.0349 0.0648 1.13E-07
PFKP 5.00E-05 0.03 0.001 0.0155 0.1476 1.14E-07
TACC3 5.00E-05 0.036 0.005 0.0205 0.117 1.20E-07
FPGS 0.0001 0.039 0.0659 0.0524 0.023 1.21E-07
WDR74 5.00E-05 0.1667 0.008 0.0873 0.028 1.22E-07
CDKN2B 5.00E-05 0.012 0.0667 0.0393 0.0632 1.24E-07
SFPQ 5.00E-05 1 0.0005 0.5002 0.005 1.25E-07
NARS 5.00E-05 0.4124 0.1465 0.2794 0.009 1.26E-07
TCOF1 5.00E-05 0.02 0.0475 0.0338 0.0756 1.28E-07
CHAF1A 0.0001 0.2581 0.0667 0.1624 0.008 1.30E-07
ALDH18A1 5.00E-05 0.2273 0.0629 0.1451 0.018 1.31E-07
MGAT4B 0.532 0.0005 0.0005 0.0005 0.0005 1.33E-07
CYP2C9 5.00E-05 0.7843 1 0.8922 0.003 1.34E-07
MRPL37 5.00E-05 0.0488 0.011 0.0299 0.0895 1.34E-07
TTBK2 5.00E-05 0.037 0.0879 0.0625 0.0438 1.37E-07
AP3D1 0.0008 0.026 0.001 0.0135 0.013 1.40E-07
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of TP53, PTEN and CDKN2A in the candidate gene-set and its
functional characteristics, are evidences in favor of the hypothesis
that we measured an excess of somatic cancer mutations. We will
be able to refute this hypothesis by using various experimental
protocols. On the other hand, it is possible that some of the
candidate genes might bear germ-line mutations and thus
constitute predisposition traits for cancer insurgence.
When we compared our results to those of the recently
published massive sequencing project, some differences emerged.
We used a larger amount of sequencing data, albeit of lower
quality since we did not use second pass sequencing data. We
obtained from dbEST a number of mismatches roughly 5 times
higher than the genome wide sequencing screens. This excess
could be due to the lower quality sequencing data in ESTs or the
higher sensitivity of our approach compared to PCR based direct
sequencing. Detection of under-represented mutations in often
heterogeneous cancer biopsies can be a technical challenge for
direct sequencing, but not for cloned ESTs.
ESTs were used in previous attempts to identify cancer related
genes. Almost invariably these approaches were based on
expression profiling, which in tumor samples is probably correlates
and late events, among the steps leading to tumor development
and progression. In a very different data mining effort on EST
sequences in cancer, Qiu and co-workers [20] measured SNP-
tumor association. Their analysis was highly focused on single
nucleotide mismatches, and restricted to known mutations
described in the SNP database and present in at least 50 EST
hits. They identified 4,865 SNP frequent in tumors (p,0.05), out
of which 327 induced amino acid substitution (cSNP). Many major
histocompatibility complex (MHC) class II molecules were present
among these coding SNPs, while none was present in our recessive
cancer gene-set. Most importantly, no landmark cancer genes,
such as TP53, PTEN and CDKN2A were present within cSNPs.
Finally, none of the SNP genes detected by Qiu et al. [20] were
present in our candidate recessive cancer gene set.
The minute cancer recessive sub-genome (,0.5%) we identified
might represent a milestone towards the identification of novel
markers for early diagnosis and prognosis. Additionally, our
mining strategy can be applied to the data which will be available
upon the sequencing of cancer genomes [22]. Finally, our work
might lead to a different equilibrium within the pool of cancer
genes, currently unbalanced towards dominant oncogenes.
Materials and Methods
EST data mining
All human coding sequences were extracted from RefSeq
mRNA database at NCBI (27,184 sequences). The dbEST
database contained more than 5.6 million human ESTs (exceeding
3,009 million nucleotides in length). The dbEST libraries (7574)
were manually annotated corresponding to the biomaterial of
origin and ESTs were subdivided in the following seven classes:
cancer tissues and cell lines (Y, 4466 libraries), normal tissues (N,
2621), cell lines of uncertain origin (C, 193), hyperplasia (B, 32),
normal tissues associated to cancer lesions (A, 33), matched normal
controls from cancer patients (M, 70) and undetermined origin (U,
159). Only the library with clear cut origin was used: i.e. 4466
cancer tissues and cell lines (Y) vs. 2621 normal tissues (N). Tissues
associated (A) or matched (M) to cancer, benign tumors (B) and
other cell lines (C) were not used. The coding sequences for each
RefSeq entry were aligned against the human dbEST database by
using BLAST. The Cancer Mutome MySQL database was
populated with a total of 43,965,904 mismatches and gaps
extracted from 3,839,543 alignments. Perl was used to develop
all the scripts and implement the system. BioPerl was used for the
BLAST procedure and parsing. BLAST parameters were set to
default (expect=1E-21) with the exception of recovering up to a
maximum of 500 alignments for each query.
Detection of point mutations in ESTs
To attenuate the problem of high sequencing error rate in
ESTs, our procedure retrieved candidate mutations only in the
region of maximum nucleotide identity to the query. Our
assumption was that an identical error rate was present in the
two EST populations, those derived from the control and those
from the cancer cells. Therefore the frequencies of mismatches due
to sequencing errors are expected to be comparable across ESTs
for the same genes. The mismatches were considered for
subsequent analysis only when present in the internal sequence
(not in the first or last ten nucleotides of the BLAST alignments).
Mismatches were then evaluated for their capabilities of changing
the amino acid residue in the correspondent codon. A single
candidate mutation was considered only once for each dbEST
library, to avoid bias due to RNA copy number. The 8972 human
genes most variable for number of mismatches (IQR.0.5) were
retained for further testing. Statistics for amino acid substitutions,
non-synonymous to synonymous nucleotide exchange rate and
frame-shifts were calculated for each human coding sequence.
Gene specific confidence limits for the respective paired t tests
were calculated by bootstrap analysis. The two bootstrap classes
were composed by random extracting 1000 times, with replace-
ment, cancer or normal status from the library classes [23,24].
In the first of three different measures, the frequencies of amino
acid substitution were compared, for each gene in normal and
cancerous tissues, by using paired t test over a 25-residues protein
window. Normalization of mismatches for the control and cancer
classes was attained by using a gene specific and local correction
factor. The correction factor was derived by dividing the
respective counts of ESTs in both classes at each nucleotide
GENE SYMBOL pDeletion pAA pNSSR pAA-NSSR pFrameshift pRecessive Cancer
PDCD6IP 5.00E-05 0.2597 0.039 0.1494 0.019 1.42E-07
CLTA 0.002 0.002 0.0693 0.0357 0.002 1.43E-07
CCNI 5.00E-05 0.03 0.0005 0.0152 0.1914 1.46E-07
ZFYVE19 5.00E-05 0.2516 0.0593 0.1555 0.019 1.48E-07
The top 154 recessive cancer genes have combined recessive cancer gene p-values lower than 1.5E-07. Alongside the Gene symbol, the p-values for each one of the 3
independent mutational events, i.e. amino acid substitution (pAA-NSSR), frameshift (pFrameshift), gene deletion (pDeletion) and the combined p-values are indicated.
The pAA-NSSR p-value was first obtained as the average of pAA and pNSSR, two non independent p-values. The global recessive cancer gene p-value
(pRecessiveCancer) was then calculated by multiplying the three independent p-values.
doi:10.1371/journal.pone.0003380.t001
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GENE SYMBOL CHROMOSOMAL LOCATION pRecessive Cancer Gene Length
Copy Number
Polymorphism
NASP chr1:45822303-45857154 1.25E-11 34851
CCNB1 chr5:68498668-68509822 2.50E-11 11154
DDX21 chr10:70385897-70414285 1.00E-10 28388
DHX9 chr1:181075073-181123505 1.00E-10 48432
GANAB chr11:62148878-62170680 1.00E-10 21802
ILF3 chr19:10625987-10664093 1.25E-10 38106
AIPL1 chr17:6267783-6279243 1.63E-10 11460
NOLC1 chr10:103901922-103913617 1.75E-10 11695
MYO1C chr17:1314229-1335801 2.25E-10 21572
NUDC chr1:27120810-27145474 3.00E-10 24664
PGAM1 chr10:99176016-99183187 5.00E-10 7171
IPO4 chr14:23719265-23727964 5.25E-10 8699
XRCC5 chr2:216682376-216779248 5.25E-10 96872
MTO1 chr6:74228208-74267896 5.60E-10 39688
ANP32B chr9:99785309-99818043 6.02E-10 32734
TP53 chr17:7512444-7531642 6.63E-10 19198
AFG3L2 chr18:12319107-12367194 7.50E-10 48087 cnp1251
FAF1 chr1:50679522-51198524 9.96E-10 519002
CALR chr19:12910422-12916303 1.00E-09 5881
SREBF2 chr22:40559051-40632319 1.00E-09 73268
XRCC6 chr22:40347240-40389998 1.12E-09 42758
ARMC8 chr3:139388837-139498909 1.25E-09 110072 cnp270
GTPBP4 chr10:1024348-1053704 1.40E-09 29356
HSPA4 chr5:132415560-132468607 1.70E-09 53047
HDAC1 chr1:32530294-32571811 1.82E-09 41517
PGD chr1:10381671-10402787 1.89E-09 21116 cnp10
VCP chr9:35046560-35062564 2.00E-09 16004
ATXN2L chr16:28741914-28756057 2.50E-09 14143 cnp1177
RPL6 chr12:111327376-111331826 2.50E-09 4450
SARS chr1:109558062-109582308 2.56E-09 24246
NCL chr2:232027703-232037449 3.00E-09 9746
PTPRC chr1:196874759-196993168 3.00E-09 118409
SMARCA4 chr19:10932605-11033952 3.00E-09 101347
CCT3 chr1:154545375-154574819 3.20E-09 29444
NET1 chr10:5478545-5490424 3.58E-09 11879
HNRPD chr4:83493490-83514173 3.74E-09 20683
SQSTM1 chr5:179180502-179197681 3.75E-09 17179
TUBB2C chr9:139255531-139257980 3.75E-09 2449
C1QBP chr17:5276822-5283195 4.00E-09 6373
TRAP1 chr16:3648038-3707599 4.00E-09 59561
ALDOA chr16:29984544-29989235 4.50E-09 4691 cnp1179
RNASEH2A chr19:12778427-12785462 4.59E-09 7035
DDX24 chr14:93587021-93617311 5.00E-09 30290
ILVBL chr19:15086786-15097577 5.00E-09 10791 cnp1283
SERPINB3 chr18:59473411-59480094 5.05E-09 6683
UQCRC1 chr3:48611435-48622102 6.60E-09 10667
EEF2 chr19:3927054-3936461 7.00E-09 9407
NUSAP1 chr15:39412360-39460537 7.43E-09 48177
DNAJC11 chr1:6616817-6684460 8.66E-09 67643
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HSP90AA1 chr14:101616827-101675839 9.00E-09 59012
MYH9 chr22:35007271-35113927 9.12E-09 106656
HK1 chr10:70748628-70831641 9.35E-09 83013
IARS chr9:94012445-94095859 1.00E-08 83414
YBX1 chr1:42920652-42940604 1.00E-08 19952
HDLBP chr2:241815351-241903927 1.12E-08 88576
EWSR1 chr22:27994016-28026515 1.25E-08 32499
DHX15 chr4:24138187-24195282 1.27E-08 57095
SERPINB4 chr18:59455474-59462482 1.28E-08 7008
POLR2A chr17:7328421-7358653 1.29E-08 30232
ALG14 chr1:95220884-95311071 1.50E-08 90187
PRMT1 chr19:54872307-54883516 1.50E-08 11209
COX4NB chr16:84369736-84390601 1.57E-08 20865
SPTBN1 chr2:54536957-54752086 1.58E-08 215129
PTPRF chr1:43769133-43861929 1.61E-08 92796
KHDRBS1 chr1:32252077-32282058 1.62E-08 29981
PABPC1 chr8:101784319-101803491 1.75E-08 19172
CTNNA1 chr5:138117005-138298621 1.80E-08 181616
DDB1 chr11:60823494-60857242 1.80E-08 33748 cnp921
GNB2L1 chr5:180596533-180603512 1.85E-08 6979
WDR1 chr4:9685060-9727671 2.00E-08 42611 cnp312
AARS chr16:68843797-68880913 2.10E-08 37116 cnp1189
NDE1 chr16:15651604-15726490 2.10E-08 74886
NQO1 chr16:68300805-68318034 2.25E-08 17229
RUVBL2 chr19:54188967-54210994 2.30E-08 22027
ZWINT chr10:57787204-57791040 2.37E-08 3836
HP1BP3 chr1:20941757-20985768 2.52E-08 44011
WDR79 chr17:7532519-7547544 2.60E-08 15025
SLC25A6 chrY:1465044-1470998 2.75E-08 5954
TYMS chr18:647650-663492 2.76E-08 15842
SLC25A3 chr12:97511533-97519908 3.00E-08 8375
ACLY chr17:37276706-37328798 3.49E-08 52092
ALDH3A1 chr17:19581891-19592200 3.50E-08 10309
TTC8 chr14:88360730-88414087 3.55E-08 53357
YME1L1 chr10:27439390-27483327 3.59E-08 43937
ATP5A1 chr18:41918107-41938197 3.61E-08 20090
MRPS2 chr9:137532374-137536337 3.69E-08 3963
HNRPH3 chr10:69761884-69772952 3.70E-08 11068
IMMT chr2:86224565-86276404 4.20E-08 51839
IMPDH2 chr3:49036771-49041879 4.35E-08 5108
NCKAP1 chr2:183497850-183611474 4.36E-08 113624 cnp194
TTLL12 chr22:41892572-41913051 4.39E-08 20479
PTEN chr10:89613174-89718511 4.45E-08 105337
WBSCR16 chr7:74094219-74127635 4.55E-08 33416 cnp627
XPNPEP1 chr10:111614513-111673192 4.65E-08 58679
SREBF1 chr17:17656110-17681050 4.78E-08 24940
CCDC5 chr18:41938322-41962296 5.02E-08 23974
DDX19B chr16:68890572-68925230 5.03E-08 34658
MAPK6 chr15:50098738-50145751 5.21E-08 47013
MAP4 chr3:47867189-48105715 5.24E-08 238526
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PHB2 chr12:6944777-6950152 5.50E-08 5375
SAE1 chr19:52325983-52405371 5.60E-08 79388
TALDO1 chr11:737431-755023 5.73E-08 17592 cnp884
AHCY chr20:32331736-32354784 5.75E-08 23048
GTF3C1 chr16:27379435-27468752 5.82E-08 89317
PRPF19 chr11:60414782-60430632 5.99E-08 15850
LASP1 chr17:34279893-34331540 6.06E-08 51647
TRIP10 chr19:6690706-6702528 6.07E-08 11822
HSPD1 chr2:198059554-198073243 6.10E-08 13689
EIF4G2 chr11:10775169-10787158 6.20E-08 11989
SFN chr1:27062219-27063534 6.38E-08 1315
TPM3 chr1:152400913-152431233 6.85E-08 30320
ZNF259 chr11:116154486-116163949 7.11E-08 9463
MAD2L2 chr1:11657124-11663774 7.45E-08 6650
GSK3B chr3:121028237-121295203 7.77E-08 266966
SH3BP5 chr3:15271360-15357905 8.27E-08 86545
CNDP2 chr18:70314576-70339336 8.53E-08 24760
PRKD2 chr19:51869412-51912224 8.69E-08 42812
CAPG chr2:85475381-85491187 8.87E-08 15806
CAPNS1 chr19:41322757-41333094 8.93E-08 10337
YY1 chr14:99774854-99814557 9.00E-08 39703
ACSL5 chr10:114125945-114178127 9.29E-08 52182
CCT6A chr7:56086871-56099176 9.55E-08 12305
RPUSD3 chr3:9854533-9860676 9.80E-08 6143
SBF1 chr22:49232101-49260320 1.02E-07 28219
YWHAE chr17:1194594-1250267 1.02E-07 55673
XPO1 chr2:61558573-61618922 1.03E-07 60349
CRELD2 chr22:48698347-48707178 1.04E-07 8831
PDCD10 chr3:168884389-168935345 1.04E-07 50956
HNRPF chr10:43201070-43223305 1.06E-07 22235
RFT1 chr3:53099850-53139503 1.08E-07 39653
BAX chr19:54149928-54156867 1.09E-07 6939
EFTUD2 chr17:40283804-40332289 1.11E-07 48485
EEF1D chr8:144733040-144750726 1.12E-07 17686
FDPS chr1:153546200-153557080 1.12E-07 10880 cnp61
CDKN2A chr9:21957751-21984490 1.13E-07 26739
PFKP chr10:3099751-3168995 1.14E-07 69244 cnp816
TACC3 chr4:1693063-1716693 1.20E-07 23630 cnp308
FPGS chr9:129605328-129616377 1.21E-07 11049
WDR74 chr11:62356959-62364204 1.22E-07 7245
CDKN2B chr9:21992905-21999312 1.24E-07 6407
SFPQ chr1:35421789-35431322 1.25E-07 9533
NARS chr18:53418891-53440175 1.26E-07 21284
TCOF1 chr5:149717427-149760063 1.28E-07 42636
CHAF1A chr19:4353659-4394393 1.30E-07 40734
ALDH18A1 chr10:97355676-97406557 1.31E-07 50881
MGAT4B chr5:179156710-179166547 1.33E-07 9837
CYP2C9 chr10:96688429-96739137 1.34E-07 50708
MRPL37 chr1:54438427-54456638 1.34E-07 18211
TTBK2 chr15:40823837-41000299 1.37E-07 176462
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gene corresponded to the sum of the T scores values exceeding the
gene-specific confidence limit (p,0.05) over the sliding window
(i.e. the area of the peaks above the threshold).
The second measure, linked to the amino acid substitution
frequency consisted in the evaluation of the selective pressure for
amino acids changes. This filter was implemented to separate
causal from bystander mutations and to further diminish the
effects of sequencing errors. The ratios of non-synonymous (NS) to
synonymous (S) nucleotide substitutions within the cancer and
normal ESTs were calculated for each gene. A paired t test was
used to compare the cancer and normal NS/S substitution ratios
at different codons. When the number of synonymous substitutions
at denominator was null, unity was added to both numerator and
denominator. Only the amino acid positions significant for
frequency of substitutions (in the amino acid substitution test
above) were evaluated here. The gene specific confidence limit at
5%, the p-values and the FDR were again computed by bootstrap,
as described above.
A third measure on point mutations was relative to the
frequency of frame-shifts, which can produce premature protein
termination or other major alterations in primary structure. In a
paired t test, analogous to that for the pAA, a 25-nt sliding window
based procedure was applied to the number of frame-shifts
induced in cancer by 1 nucleotide insertions or deletions. Longer
DNA alterations were not recorded, and were extremely rare. The
gene p-values for such frame-shifts in cancer were again computed
by bootstrap and defined as pFrameshift.
ESTs P-value and false detection rate calculation
Procedures were devised for calculation of gene-specific p-values
and false detection rates in each one of the described approaches.
Bootstrap analysis was used to compute the adjusted probability
that a human gene was affected in cancer but not in normal ESTs
[23,24]. The resampling test allowed us to define confidence limits
for each different gene and to effectively tackle local issues such as
DNA composition, CpG occurrence, and protein or gene length.
For the point mutation analyses, the resampling procedure was
performed only on the protein residues found to be above T
threshold (p,0.05). A range of bootstraps were performed to
choose the lowest number of resampling cycles yielding stable p-
values through a short gene list and 1000 cycles were found to be a
satisfactory requirement. The ESTs belonging to cancer and
normal classes were randomly subdivided to form two simulated
classes with the same size as the original ones. The gene specific p-
value was defined as the frequency at which the resampling test
scored equal or better than the real test. Null p-values were set to
half of the lowest p-value in the respective simulations.
Detection of deletions in array CGH
744 comparative genomic hybridization arrays were studied
(537 samples from GEO and 207 from SMD). All platforms were
2-channel based, data were downloaded as normalized values, and
probes were indexed by gene symbol. Gene data and annotations
were stored in the GeoSoft database. All normalized log ratios
were converted to log2 ratios, with the cancer value at the
numerator and the control value at the denominator. Pre-filtering
of genes was performed on standard deviation, to exclude the
genes which did not show high variation of their genomic profiles
(std dev,0.2). Genes were scored when measured in at least 300
tumors. Deleted cancer genes were expected to have log2 ratios
lower than the 5
th percentile of the bootstrapped log2 ratios;
amplified genes log2 ratios higher than the 95
th percentile of the
bootstrapped values. Bootstrap analysis was used (10,000 random
swaps of tumor and control channels) to obtain gene specific p-
values and confidence limits for deletion and amplification.
Point Mutation and aCGH combined p-values
Finally, the p-values obtained by the three different tests: pAA-
NSSR, pFrameshift and pDeletion were multiplied together to
compute the global pRecessiveCancer p-value. This p-value was
used to sort the human genes by their propensity to bear mutations
in cancer. One hundred and 54 genes were selected with p-value
below 1.5610
27. One hundred resampling cycles were performed
by randomly associating p-values for each mutation test and
yielded a false detection rate of 39%. EASE (http://david.abcc.
ncifcrf.gov) and BinGO (Cytoscape plugin) were used for Gene
Ontology analysis. Hyper-geometric test with Benjamini and
Hochberg false discovery rate correction was used in BinGO [25].
Supporting Information
Figure S1 Genomic structures are correctly identified by the
aCGH protocol. Track analysis in UCSC Genome Browser of
Xp22 Pseudo-Autosomal Region 1 (PAR1). The Pseudo-Autoso-
mal Region 1 is correctly identified as normal (diploid) by the
array CGH analysis, while the rest of X chromosome is reported,
also as expected, ‘‘pseudo-amplified’’. The chromosome X genes 3
prime of PAR1 appear as amplified because their DNA copy
number is higher than expected when compared to the respective
average DNA copy number in the whole, mixed sex, tumour
population.
Found at: doi:10.1371/journal.pone.0003380.s001 (0.31 MB TIF)
Figure S2 Distribution of gene size in the candidate recessive
cancer gene-set. The recessive cancer gene sizes do not differ
significantly from the gene sizes in the human genome (most
common genes range between 32 and 128 kb).
GENE SYMBOL CHROMOSOMAL LOCATION pRecessive Cancer Gene Length
Copy Number
Polymorphism
AP3D1 chr19:2051993-2102556 1.40E-07 50563
PDCD6IP chr3:33814560-33886198 1.42E-07 71638
CLTA chr9:36180891-36202055 1.43E-07 21164
CCNI chr4:78188198-78216149 1.46E-07 27951
ZFYVE19 chr15:38886565-38894059 1.48E-07 7494
The top 154 genes have combined recessive cancer gene p-values lower than 1.5610
27 (FDR=0.39). Alongside the gene symbol, genome coordinates, gene length,
cancer gene p-value and eventual copy number polymorphic site are reported.
doi:10.1371/journal.pone.0003380.t002
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Table S1 Array CGH datasets.
Found at: doi:10.1371/journal.pone.0003380.s003 (0.04 MB
DOC)
Table S2 Functional (Gene ontology, biological process) chart of
the candidate cancer recessive genes, FDR,0.5
Found at: doi:10.1371/journal.pone.0003380.s004 (0.22 MB
DOC)
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